Pharmaceutical Company Aims to Serve More Than 60 Million Patients by 2030

LONDON — Pharmaceutical company Novo Nordisk aims to serve more than 60 million patients worldwide by 2030. The target forms part of its strategy to expand access to treatment, develop its product portfolio and drive sustainable business growth.

The strategy was presented at the Capital Markets Day (CMD) 2026, held in London on 21 September 2026. Novo Nordisk’s management used the event to outline an update to the company’s strategy and its medium-term targets through to 2030.

To broaden its product portfolio, Novo Nordisk aims to launch more than five medicines with blockbuster sales potential across various indications by 2030. It is also targeting potential sales of more than 150 billion Danish kroner from its drug development portfolio by 2035.

The company is also targeting at least five Phase III clinical development programmes in obesity and diabetes, and at least five Phase III programmes in other therapeutic areas. These targets include both new and existing development programmes.

For business growth, Novo Nordisk is targeting average annual revenue growth over 2026–2030 in line with comparable companies in the pharmaceutical industry. It also plans to increase production capacity so it can provide oral GLP-1 therapies to ten times as many people with obesity.

To sustain shareholder returns, Novo Nordisk is targeting a broadly stable operating margin while maintaining an attractive dividend per share.

The strategy update coincides with the company’s refreshed corporate identity, featuring the message “Lasting Health Starts Now” and the use of Novo as its sole identity. The company also introduced The Novo Way as part of a workplace culture refresh intended to promote focus, speed and impact in executing its business strategy.

Novo Nordisk said these targets represent strategic ambitions based on conditions in 2026. They are subject to uncertainty and are not intended as formal financial projections or guidance.